2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1462-1474

  Vansteenkiste, J ^a   Crino L ^b   Dooms, C ^a   Douillard, J Y ^c   Faivre Finn, C ^d   Lim, E ^e   Rocco, G ^f   Senan, S ^g   van Schil, P ^h   Veronesi, G ⁱ   Stahel, R ^j   Peters, S ^k   Felip, E ^l   Kerr, Keith ^m   Besse, Benjamin ⁿ   Eberhardt, Wilfried ^o   Edelman, Martin ^p   Mok, Tony ^q   O'Byrne, Ken ^r   Novello, Silvia ^s   Bubendorf, Lukas ^t   Marchetti, Antonio ^u   Baas, Paul ^t   Reck, Martin ^v   Syrigos, Konstantinos ^w   Paz Ares, Luis ^x   Smit, Egbert F ^g   Meldgaard, Peter ^y   Adjei, Alex ^z   Nicolson, Marianne ^aa   Weder, Walter ^j   de Ruysscher, Dirk ^a   Le Pechoux, Cecile ⁿ   de Leyn, Paul ^a   Westeel, Virginie ^ab   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c Department of Medical Oncology Integrated Centers of Oncology R Gauducheau   (France)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁿ INSTITUT GUSTAVE ROUSSY   (France)

^o UNIVERSITY HOSPITAL ESSEN   (Germany)

^p UNIVERSITY OF NEW MEXICO   (United States)

^q CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^r ST JAMES S HOSPITAL   (Ireland)

^s SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^t ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^u UNIVERSITY OF CHIETI   (Italy)

^v KRANKENHAUS GROSSHANSDORF   (Germany)

^w First Department of Thoracic Surgery   (Greece)

^x HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^y AARHUS UNIVERSITY HOSPITAL   (Denmark)

^z ROSWELL PARK CANCER INSTITUTE   (United States)

^aa ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^ab UNIVERSITÉ DE FRANCHE COMTÉ   (France)

more..

Author keywords

Consensus; Early disease; ESMO; Lung cancer; Non small cell lung cancer

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE; NAVELBINE; TUMOR MARKER;

ADJUVANT THERAPY; ARTICLE; BRONCHUS STENOSIS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CARDIOPULMONARY EXERCISE TEST; CLINICAL ASSESSMENT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; COUGHING; EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY; FATIGUE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEMOPTYSIS; HIGH RISK POPULATION; HUMAN; INCIDENCE; LOW DOSE COMPUTED TOMOGRAPHY; LUNG NON SMALL CELL CANCER; NECROSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RIB FRACTURE; RISK ASSESSMENT; SKIN IRRITATION; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC TREATMENT; TUMOR VOLUME; VIDEO ASSISTED THORACOSCOPIC SURGERY; CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS; CYTODIAGNOSIS; EARLY DIAGNOSIS; LUNG NEOPLASMS; LUNG RESECTION; PATHOLOGY; PHYSIOLOGIC MONITORING; PRACTICE GUIDELINE; PROCEDURES; RADIOSURGERY; STANDARDS; UTILIZATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; HIGH RISK PATIENT; INTERMETHOD COMPARISON; LUNG CARCINOGENESIS; LUNG NODULE; LUNG SURGERY; MEDICAL DECISION MAKING; MEDICAL SERVICE; MEDICAL SOCIETY; MOLECULAR PATHOLOGY; NON SMALL CELL LUNG CANCER; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; OUTCOME ASSESSMENT; RISK FACTOR; ROBOTICS; SALVAGE THERAPY; SURGICAL RISK; TREATMENT INDICATION;

CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; PNEUMONECTOMY; RADIOSURGERY; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84904545741     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu089     Document Type: Article

References (82)

1. Felip E, Gridelli C, Baas P et al. Metastatic non-small cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011; 22: 1507-1519.
2. Stahel R, Thatcher N, Fruh M et al. 1st ESMO consensus conference in lung cancer; Lugano 2010: small cell lung cancer. Ann Oncol 2011; 22: 1973-1980.
3. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
4. Vansteenkiste J, De Ruysscher D, Eberhardt W et al. Early and locally advanced non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi89-vi98.
5. Fontana RS, Sanderson DR, Taylor WF et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis 1984; 130: 561-565.
6. Frost JK, Ball WC Jr, Levin ML et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the John Hopkins study. Am Rev Respir Dis 1984; 130: 549-554.
7. Flehinger BJ, Melamed MR, Zaman MB et al. Early lung cancer detection: results of the initial (prevalance) radiologic and cytologic screening in the Memorial Sloan Kettering study. Am Rev Respir Dis 1984; 130: 555-560.
8. Kubik A, Polak J. Lung cancer detection. Results of a randomized prospective study in Czechoslovakia. Cancer 1986; 57: 2427-2437.
9. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with lowdose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
10. NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 1, 2011. 2011.
11. Field JK, Smith RA, Aberle DR et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol 2012; 7: 10-19.
12. Smith RA, Brooks D, Cokkinides V et al. Cancer screening in the United States 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013; 63: 88-105.
13. Bach PB, Mirkin JN, Oliver TK et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012; 307: 2418-2429.
14. Maisonneuve P, Bagnardi V, Bellomi M et al. Lung cancer risk prediction to select smokers for screening CT-a model based on the Italian COSMOS trial. Cancer Prev Res 2011; 4: 1778-1789.
15. Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 2011; 155: 137-144.
16. Patel VK, Naik SK, Naidich DP et al. A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 2: pretest probability and algorithm. Chest 2013; 143: 840-846.
17. Van Klaveren RJ, Oudkerk M, Prokop M et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009; 361: 2221-2229.
18. van't Westeinde SC, de Koning HJ, Thunnissen FB et al. The role of the 18Ffluorodeoxyglucose- positron emission tomography scan in the Nederlands Leuvens Longkanker Screenings Onderzoek Lung Cancer Screening Trial. J Thorac Oncol 2011; 6: 1704-1712.
19. Ashraf H, Dirksen A, Loft A et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax 2011; 66: 315-319.
20. Macmahon H, Austin JH, Gamsu G et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237: 395-400.
21. Naidich DP, Bankier AA, Macmahon H et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013; 266: 304-317.
22. Herder GJ, Van Tinteren H, Golding RP et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18Ffluorodeoxyglucose positron emission tomography. Chest 2005; 128: 2490-2496.
23. Lim E, Baldwin D, Beckles M et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010; 65(Suppl 3): iii1-iii27.
24. Palma D, Visser O, Lagerwaard FJ et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010; 28: 5153-5159.
25. Khakwani A, Rich AL, Tata LJ et al. The pathological confirmation rate of lung cancer in England using the NLCA database. Lung Cancer 2013; 79: 125-131.
26. Gould MK, Donington J, Lynch WR et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(Suppl 5): e93S-e120S.
27. Verstegen NE, Oosterhuis JW, Palma DA et al. Stage I-II non-small cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity scorematched analysis. Ann Oncol 2013; 24: 1543-1548.
28. Verstegen NE, Lagerwaard FJ, Haasbeek CJ et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol 2011; 101: 250-254.
29. Senan S, Paul MA, Lagerwaard FJ. Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy? Lancet Oncol 2013; 14: e270-e274.
30. Lim E, Beckles M, Warburton C, Baldwin D. Cardiopulmonary exercise testing for the selection of patients undergoing surgery for lung cancer: friend or foe? Thorax 2010; 65: 847-849.
31. Loewen GM, Watson D, Kohman L et al. Preoperative exercise VO2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol. J Thorac Oncol 2007; 2: 619-625.
32. Falcoz PE, Conti M, Brouchet L et al. The Thoracic Surgery Scoring System (Thoracoscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. J Thorac Cardiovasc Surg 2007; 133: 325-332.
33. Brunelli A, Varela G, Salati M et al. Recalibration of the revised cardiac risk index in lung resection candidates. Ann Thorac Surg 2010; 90: 199-203.
34. Brunelli A, Cassivi SD, Fibla J et al. External validation of the recalibrated thoracic revised cardiac risk index for predicting the risk of major cardiac complications after lung resection. Ann Thorac Surg 2011; 92: 445-448.
35. Brunelli A, Charloux A, Bolliger CT et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009; 34: 17-41.
36. Choong CK, Meyers BF, Battafarano RJ et al. Lung cancer resection combined with lung volume reduction in patients with severe emphysema. J Thorac Cardiovasc Surg 2004; 127: 1323-1331.
37. Yacoub WN, Meyers BF. Surgical resection in combination with lung volume reduction surgery for stage I non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2010; 22: 38-43.
38. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
39. Travis WD, Brambilla E, Van Schil P et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J 2011; 38: 239-243.
40. Van Schil PE, Asamura H, Rusch VW et al. Surgical implications of the new IASLC/ ATS/ERS adenocarcinoma classification. Eur Respir J 2012; 39: 478-486.
41. Rami-Porta R, Tsuboi M. Sublobar resection for lung cancer. Eur Respir J 2009; 33: 426-435.
42. Blasberg JD, Pass HI, Donington JS. Sublobar resection: a movement from the Lung Cancer Study Group. J Thorac Oncol 2010; 5: 1583-1593.
43. Fan J, Wang L, Jiang GN, Gao W. Sublobectomy versus lobectomy for stage I nonsmall cell lung cancer, a meta-analysis of published studies. Ann Surg Oncol 2012; 19: 661-668.
44. Nomori H, Iwatani K, Kobayashi H et al. Omission of mediastinal lymph node dissection in lung cancer: its techniques and diagnostic procedures. Ann Thorac Cardiovasc Surg 2006; 12: 83-88.
45. Veronesi G, Maisonneuve P, Pelosi G et al. Screening-detected lung cancers: is systematic nodal dissection always essential? J Thorac Oncol 2011; 6: 525-530.
46. Korst RJ, Ginsberg RJ, Ailawadi M et al. Lobectomy improves ventilatory function in selected patients with severe COPD. Ann Thorac Surg 1998; 66: 898-902.
47. Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and metaanalysis of randomized and non-randomized trials on safety and efficacy of videoassisted thoracic surgery lobectomy for early-stage non-small cell lung cancer. J Clin Oncol 2009; 27: 2553-2562.
48. Cao C, Manganas C, Ang SC et al. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity scorematched patients. Interact Cardiovasc Thorac Surg 2013; 16: 244-249.
49. Veronesi G, Agoglia BG, Melfi F et al. Experience with robotic lobectomy for lung cancer. Innovations 2011; 6: 355-360.
50. Park BJ, Melfi F, Mussi A et al. Robotic lobectomy for non-small cell lung cancer (NSCLC): long-term oncologic results. J Thorac Cardiovasc Surg 2012; 143: 383-389.
51. Cerfolio RJ, Bryant AS, Skylizard L, Minnich DJ. Initial consecutive experience of completely portal robotic pulmonary resection with 4 arms. J Thorac Cardiovasc Surg 2011; 142: 740-746.
52. Louie BE, Farivar AS, Aye RW, Vallières E. Early experience with robotic lung resection results in similar operative outcomes and morbidity when compared with matched video-assisted thoracoscopic surgery cases. Ann Thorac Surg 2012; 93: 1598-1604.
53. Battafarano RJ, Meyers BF, Guthrie TJ et al. Surgical resection of multifocal nonsmall cell lung cancer is associated with prolonged survival. Ann Thorac Surg 2002; 74: 988-994.
54. Fabian T, Bryant AS, Mouhlas AL et al. Survival after resection of synchronous non-small cell lung cancer. J Thorac Cardiovasc Surg 2011; 142: 547-553.
55. Voltolini L, Rapicetta C, Luzzi L et al. Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup. Eur J Cardiothorac Surg 2010; 37: 1198-1204.
56. Okada M, Tsubota N, Yoshimura M et al. Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Ann Thorac Surg 1999; 68: 326-330.
57. Tanvetyanon T, Finley DJ, Fabian T et al. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Ann Oncol 2013; 24: 889-894.
58. The International Adjuvant Lung Cancer Trial Collaborative Group, Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004; 350: 351-360.
59. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
60. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727.
61. Pepe C, Hasan B, Winton TL et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007; 25: 1553-1561.
62. Fruh M, Rolland E, Pignon JP et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer. J Clin Oncol 2008; 26: 3573-3581.
63. Booth CM, Shepherd FA, Peng Y et al. Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study. Cancer 2013; 119: 1243-1250.
64. Bradley J. New territory: surgical salvage for stereotactic body radiation therapy failures in lung cancer. J Thorac Oncol 2010; 5: 1879-1880.
65. Chen F, Matsuo Y, Yoshizawa A et al. Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol 2010; 5: 1999-2002.
66. Neri S, Takahashi Y, Terashi T et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol 2010; 5: 2003-2007.
67. Hamamoto Y, Kataoka M, Yamashita M et al. Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment. Jpn J Radiol 2012; 30: 671-675.
68. Van Schil PE. Salvage surgery after stereotactic radiotherapy: a new challenge for thoracic surgeons. J Thorac Oncol 2010; 5: 1881-1882.
69. Bongers EM, Haasbeek CJ, Lagerwaard FJ et al. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. J Thorac Oncol 2011; 6: 2052-2057.
70. Van Schil PE. Results of surgery for lung cancer compared with radiotherapy: do we speak the same language. J Thorac Oncol 2013; 8: 129-130.
71. Simone CB 2nd, Wildt B, Haas AR et al. Stereotactic body radiation therapy for lung cancer. Chest 2013; 143: 1784-1790.
72. Lou F, Huang J, Sima CS et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg 2013; 145: 75-81.
73. Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998; 90: 1335-1345.
74. Demicheli R, Fornili M, Ambrogi F et al. Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. J Thorac Oncol 2012; 7: 723-730.
75. Toba H, Sakiyama S, Otsuka H et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small cell lung cancer patients. Interact Cardiovasc Thorac Surg 2012; 15: 859-864.
76. Huang K, Dahele M, Senan S et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)-can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012; 102: 335-342.
77. Dahele M, Palma D, Lagerwaard F et al. Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol 2011; 6: 1221-1228.
78. Takeda A, Kunieda E, Takeda T et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2008; 70: 1057-1065.
79. Hoopes DJ, Tann M, Fletcher JW et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer. Lung Cancer 2007; 56: 229-234.
80. Takeda A, Kunieda E, Fujii H et al. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small cell lung cancer. Lung Cancer 2013; 79: 248-253.
81. Nakajima N, Sugawara Y, Kataoka M et al. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med 2013; 27: 261-270.
82. Zhang X, Liu H, Balter P et al. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 83: 1558-1565.